Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06997549 · ClinicalTrials.gov registry record
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
A clinical trial of Depression and OCD, sponsored by Neuronetics.
- Recruiting
- Registry status
- 12,000
- Enrollment target
- 1
- Study location
NCT06997549: Recruiting study of Depression and OCD, sponsored by Neuronetics.
NCT06997549 is a study of Depression and OCD that is actively recruiting participants, run by Neuronetics. The registered enrollment target is 12,000 participants, above the 769-participant average among 679 other Depression trials with a reported enrollment target (1460% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06997549, a study of Depression and OCD, is actively recruiting participants, sponsored by Neuronetics.
- RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness
Primary Outcome
real-world efficacy of NeuroStar TMS as compared to Esketamine in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9
Conditions Studied
Interventions
- DEVICE Patients treated with NeuroStar TMS
- DRUG Patients treated with Esketamine
Study Locations (1)
Pennsylvania
- Neuronetics - Malvern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2035-12 |
What NCT06997549 shows while recruiting
NCT06997549 is an observational study that tracks outcomes without assigning an intervention. Its 12,000 participants enrollment target places it among the larger protocols in the corpus, above the 769-participant average among 679 other Depression trials with a reported enrollment target (1460% higher).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Patients treated with NeuroStar TMS is the first listed.
NCT06997549 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06997549 about?
NCT06997549 is a clinical study titled "Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments". The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness
What is the current status of trial NCT06997549?
This trial is currently recruiting. The enrollment target is 12,000 participants. The study started on 2025-05-15. Estimated completion is 2035-12.
What conditions does trial NCT06997549 study?
This clinical trial studies the following conditions: Depression, OCD, Anxiety Depression.
What interventions are being tested in trial NCT06997549?
The interventions under investigation include: Patients treated with NeuroStar TMS (DEVICE), Patients treated with Esketamine (DRUG).
Who is sponsoring clinical trial NCT06997549?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06997549 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06997549's enrollment target sits among peer trials
12,000 6th of 679 higher than 674 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy